Therefore, we aimed to further characterise the expression patterns and define a molecular function for LXN in the normal and malignant prostate in order to determine how potential loss of LXN signalling in advanced prostate cancer might be exploited as a rational therapeutic target in CaP. The gene discussed is LXN; the disease is prostate carcinoma.